Can a targeted radiation combo boost rectal cancer remission?

NCT ID NCT07057089

First seen Jul 31, 2026 ยท Last updated Jul 31, 2026

Summary

This trial is testing whether a more focused radiation field, combined with chemotherapy and an immunotherapy drug called camrelizumab, can improve outcomes for people with a certain type of locally advanced rectal cancer. The study will compare this new approach to a standard treatment that uses a larger radiation field. The main goal is to see if the new combination leads to a higher rate of complete response, meaning the cancer disappears or shrinks significantly before surgery.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
A combination of capecitabine (chemotherapy), camrelizumab (PD-1 inhibitor immunotherapy), and involved-field radiation therapy, followed by surgery.
What this could lead to
If successful, this approach could increase the chance of eliminating the tumor before surgery, potentially allowing some patients to avoid surgery or preserve more organs.
What could go wrong
This is a phase 2 trial with a relatively small number of participants. The combination may not improve outcomes and could increase side effects compared to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • the Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.